Introduction {#dmw036s6}
============

As early as 1979, Henderson et al. hypothesized that a relative excess of estrogen, in particular at the time of testicle differentiation, is a major risk factor for testicular cancer ([@dmw036C35]). Fourteen years later, Sharpe and Skakkebaek proposed that not only testicular cancer but also other male reproductive disorders such as cryptorchidism, hypospadias and low sperm counts may share a common fetal origin and that environmental exposure to chemicals with actions mimicking estrogens might play a pivotal role ([@dmw036C77]). The underlying mechanisms were thought to include increased negative feedback on the fetal pituitary resulting in reduced levels of gonadotrophins leading to disruption of normal development of the male fetal gonad during the late phase of the first trimester of pregnancy ([@dmw036C77]). This so-called estrogen hypothesis has been scrutinized by a large number of studies addressing the risk of male reproductive disorders in boys who, during pregnancy, were exposed to high or low levels of estrogens because of twin pregnancy, first parity, preeclampsia, hyperemesis or intended or incidental treatment with synthetic hormones during first trimester. Three literature reviews provide no support for the estrogen hypothesis except that testicular cancer seems related to high prenatal estrogen exposure ([@dmw036C73]; [@dmw036C84]; [@dmw036C54]). In particular, it is notable that prenatal exposure to the highly potent synthetic estrogen diethylstilbestrol is only associated with low sperm count at high doses ([@dmw036C27]; [@dmw036C45]). Subsequently a capacious amount of experimental research has indicated that adverse health effects, including male reproductive disorders, may be related to endocrine disruption of fetal development through xenobiotic interaction with steroid hormone receptors or through interference with the synthesis, secretion, transport, metabolism or degradation of natural hormones ([@dmw036C22]; [@dmw036C102]). This broader endocrine disruption hypothesis with focus on environmental pollutants has gained tremendous public and scientific attention in the USA and the European Union over the past 15 years. Numerous narrative reviews and consensus statements have discussed supporting and contradicting evidence based on data of secular trends of male reproductive health outcomes, wildlife impact and exposure levels in various populations, in addition to the large body of *in vitro* and *in vivo* experimental data ([@dmw036C22]; [@dmw036C5]; [@dmw036C14]; [@dmw036C21]; [@dmw036C43]; [@dmw036C65]; [@dmw036C75]; [@dmw036C76]; [@dmw036C82]; [@dmw036C86]; [@dmw036C90]; [@dmw036C93]; [@dmw036C101]; [@dmw036C102]). It is particularly noteworthy that biomonitoring data from all over the world provide unequivocal documentation of human exposure to a range of xenobiotic substances including persistent compounds ([@dmw036C29]; [@dmw036C47]; [@dmw036C30]; [@dmw036C37]; [@dmw036C48]; [@dmw036C52]) as well as rapidly metabolized and excreted compounds that reach steady state concentrations in human blood and tissues because of continuous exposure ([@dmw036C1]; [@dmw036C104]). These xenobiotic compounds have been released into the environment intentionally via the widespread application of pesticides or unintentionally by either degradation of industrial products and building materials or by leakage of packing materials into food items ([@dmw036C63]). New exposure pathways are described regularly. For instance, it has recently been reported that semi-volatile polychlorinated biphenyls (PCBs) represent an important inhalation exposure pathway for residents living in PCB contaminated homes containing PCB in calking material, paints and sealant used \>40 years ago ([@dmw036C24]; [@dmw036C61]). Exposure by inhalation and possibly through the skin may more than double the PCB body burden in individuals exposed at the residence or at school ([@dmw036C61]). Considering the mounting evidence that numerous of these environmental xenobiotics exhibit endocrine activity in *in vitro* and *in vivo* assays, there is basis for substantial concern regarding the potential health effects in humans ([@dmw036C25]; [@dmw036C60]; [@dmw036C92]), even if alarming reports on, for instance, declining sperm counts are circumstantial or not corroborated ([@dmw036C10]) and the best evidence we have is reassuring ([@dmw036C39]).

However, the epidemiological data on the adverse health effects are sparse, particularly regarding links with prenatal and postnatal exposure, and there is presently no consensus. In 2012, a Global Assessment of the State-of-the-Science of Endocrine Disrupters commissioned by the World Health Organization and United Nations Environment Program concluded that the direct evidence for endocrine disrupting effects with adverse health effects because of exposure to xenobiotic substances is limited in humans, but emphasized the need for continuous attention ([@dmw036C22]; [@dmw036C102]). As several epidemiological studies addressing this issue have been published over the past 10 years, a systematic evaluation of the epidemiological evidence on effects of environmental endocrine disrupting xenobiotics including quantitative meta-analyses of data, where feasible, has now become timely ([@dmw036C6]).

Therefore, the objective of this review was to identify and evaluate the epidemiological evidence linking adverse reproductive health disorders with *in utero* or early postnatal exposure to xenobiotic endocrine disrupting compounds. The key eligibility criteria are documentation of exposure contrast by chemical measurements of the compounds in maternal blood or other biospecimens indicative of fetal or infant exposure. Specifically, we address the following four hypotheses on the risk of adverse male reproductive outcomes following prenatal and postnatal environmental exposure to industrial chemicals classified as endocrine disrupting substances ([@dmw036C56]): (i) that all compounds regardless of specific endocrine disrupting properties carry a risk of reproductive disorders considered as one outcome entity; (ii) that specific compounds are heterogeneous with respect to reproductive disorders considered as one entity; (iii) that all compounds regardless of specific endocrine disrupting properties carry a risk for specific outcomes; and (iv) that specific compounds carry a risk for specific outcomes.

Methods {#dmw036s7}
=======

The review was conducted and reported in accordance with the MOOSE guidelines for Meta-analyses and Systematic reviews of Observational Studies ([@dmw036C85]).

Protocol and registration {#dmw036s7a}
-------------------------

A review protocol was registered at PROSPERO.org with registration number CRD4201603742 prior to initiation of the review process, on 12 April 2016 with amendments on 12 May 2016 (CRD420160374X). The amendments specified the four main hypotheses, provided details on sensitivity analyses and discarded the initial idea to analyze data according to estrogenic or anti-androgenic activity of measured compounds which proved non-feasible. The protocol was updated before the review process and data analysis were initiated.

Information sources {#dmw036s7b}
-------------------

The databases PubMed and Embase were used as they cover the vast majority of relevant journals for the subject.

Eligibility criteria {#dmw036s7c}
--------------------

We conducted a systematic search of original peer-reviewed original papers in English published between 1966 and 12 April 2016 to identify journal articles providing quantitative data on the association between xenobiotic endocrine disrupting chemicals and male reproductive disorders in humans. The complete search specification is provided in the online [Supplementary Table 1](http://HUMUPD.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmw036/-/DC1). Eligibility criteria for inclusion in the systematic review were as follows. Exposures: Chemicals that by the European Commission are classified as Category 1 endocrine disruptors with high concern in terms of human or wildlife exposure ([@dmw036C56]). Category 1 compounds are defined as chemicals where at least one study has shown endocrine effects in an intact organism. The EU report lists 60 Category 1 substances (29 chemical groups) that are highly persistent or have high current production volume ([@dmw036C56]). In addition we include the polyfluorinated chemicals, a group of ubiquitous biopersistent emerging endocrine disruptors ([@dmw036C100]) that are receiving increasing attention. Table [I](#dmw036TB1){ref-type="table"} lists the specific chemical substances with abbreviations that are referenced in the text and in Tables [II](#dmw036TB2){ref-type="table"}--[VII](#dmw036TB7){ref-type="table"}.Outcomes: Cryptorchidism (one or both testicles undescended) ascertained at birth or during childhood, hypospadias, testicular cancer regardless of histological subgroup, and sperm count (number of spermatozoa per volume or mass unit of seminal fluid).Exposure to specific chemicals *in utero* or in the first year of life (postnatal exposure) documented by measurements in biological specimens (maternal blood or urine, placenta or fat tissue as well as amnion fluid, cord blood or breast milk). In addition serum concentrations in adult life as proxies for fetal or early life exposure were also included for testicular cancer.Outcome ascertainment by medical standardized examination or antecedent medical records or reporting to health registries.Risk estimates (rate risk \[RR\], OR, hazard ratio \[HR\]) for an outcome according to higher versus lower levels of prenatal and postnatal exposure defined by exposure contrasts within the given study. Studies reporting alternative measures of association such as difference in mean values of exposure levels in cases and controls were also included, and the authors were contacted to get risk estimates ([@dmw036C36]; [@dmw036C20]; [@dmw036C53]; [@dmw036C17]; [@dmw036C23]; [@dmw036C40]; [@dmw036C98]). Several authors responded positively but reanalysis of the original data could not be accomplished within the given time-frame and the studies were therefore not included in the present review. Table IList of specific chemical substances with abbreviations.Bisphenol A4,4′-(Propan-2,2-diyl)diphenolmBPMono-n-butyl-phthalateChlordane mixcis-heptachlordane, cis-chlordane, ocychlordane, trans-nonachlordane, cis-nonachlordaneDBPDi-n-butyl-phthalateDDE1,1-Dichloro-2,2-bis(p-chlorophenyl)ethyleneo,p′-DDT1,1,1-Tricholoro-2-(p-chlororphenyl)-2-(o-chlorophenyl)ethanep,p′-DDT1,1,1-Trichloro-2,2-bis(p-chlorophenyl)ethaneDEHPDi-(2-ethylhexyl)phthalateDieldrinDerivate of norbornadiene and hexachlorocyclopentadieneHCBHexachlorobenzeneHCEHeptachlor epoxideHCCHb-HexachlorocyclohexaneMEHPMono-(2-ethylhexyl)phthalate5cx-MEPPDi(2-ethylhexyl)phthalate \[metabolite of DEHP\]7cx-MMeHPMono(4-ethyl-7-carboxylheptyl)phthalate \[metabolite of DiNP\]MirexDimerization derivate of hexachlorocyclopentadienen-NPn-Nonylphenolt-OPt-OctylphenolPBBPolybrominated biphenylPBDEPolybrominated diphenyl etherPCBPolychlorinated biphenylPCDD/FsPolychlorinated dibenzo-p-dioxins/furansPFOSPerfluorooctane sulfonic acidPFOAPerfluorooctanoic acidTCDD2,3,7,8-Tetrachlorodibenzo-p-dioxin Table IICharacteristics and risk estimates for 10 case-referent studies (18 risk estimates) addressing the risk of cryptorchidism following prenatal and postnatal exposure to endocrine disrupting chemicals.ReferenceLocationStudy population*N* Cases/ referentsExposure mediumExposure contrastSubstanceOR95% CICR^[a](#dmw036tfn1){ref-type="table-fn"}^Bias^[b](#dmw036tfn2){ref-type="table-fn"}^[@dmw036C49]USA (12 centers)Collaborative Perinatal Project219/552Third trimester serumHighest versus lowest quintilesp,p′-DDE1.300.70--2.2490[@dmw036C67])USA (12 centers)Collaborative Perinatal Project219/564Third trimester serum75--90 percentile versus 0--10 percentileb-HCCH2.081.08--4.0190HCE0.820.41--1.65HCB0.850.52--1.40[@dmw036C57])USA (12 centers)Collaborative Perinatal Project230/593Third trimester serumHighest quartile versus lowestPCB (sum of 11 congeners)1.410.90--2.2080[@dmw036C91]USA (12 centers)Collaborative Perinatal Project217/557Third trimester serumHighest quartile versus lowest*trans*-nonachlor1.220.70--2.1290Oxychlordane0.950.55--1.64[@dmw036C7]USA, San FranciscoChild Health and Development Study75/283Maternal serumHighest versus lowest quartilep,p′- DDT1.010.44--2.2891p,p′- DDE1.340.51--3.48[@dmw036C13]France, NiceNewborns at maternity clinics in Nice and Grasse.56/69ColostrumHighest versus lowest. Three categoriesp,p′-DDE2.160.94--4.9871PCB (seven congeners)2.741.15--6.53mBP2.130.66--6.83[@dmw036C83]USA, MichiganMichigan Long-term PBB Study9/464Maternal serumHighest versus lowest (\<LOD). Three categoriesPBB-153 (Includes hypospadias)0.500.10--4.7041[@dmw036C97]Denmark and FinlandDanish--Finnish prospective Birth Cohort Study107/108Cord bloodHighest tertile versus lowestPFOS0.830.39--1.7990PFOA0.460.20--1.2090[@dmw036C38]DenmarkPregnancy screening registry, Serum Institute270/300Second trimester amnion fluidHighest tertile versus lowest5cx-MEPP0.900.57--1.41917cx-MMeHP1.280.80--2.01[@dmw036C88]DenmarkPregnancy screening registry, Serum Institute270/300Second trimester amnion fluidHighest tertile versus lowestPFOS1.010.66--1.5391[^1][^2] Table IIICharacteristics of 10 case-referent studies (21 risk estimates) addressing the risk of hypospadias following prenatal and postnatal exposure to endocrine disrupting chemicals.ReferenceLocationStudy population*N* Cases/ ReferentsExposure mediumExposure contrastSubstanceOR95% CIMeta- analysisCR^[a](#dmw036tfn3){ref-type="table-fn"}^Bias^[b](#dmw036tfn4){ref-type="table-fn"}^[@dmw036C49]USA (12 centers)Collaborative Perinatal Project199/552Third trimester serumHighest versus lowest quintilesp,p′-DDE1.20.60--2.40Yes80[@dmw036C57]USA (12 centers)Collaborative Perinatal Project201/593Third trimester serumHighest versus lowest quartilePCB (sum of 11 congeners)1.691.06--2.68Yes81[@dmw036C91]USA (12 centers)Collaborative Perinatal Project197/557Third trimester serumHighest quartile versus lowest*trans*-nonachlor1.080.62--1.89Yes90Oxychlordane1.240.69--2.22Yes9[@dmw036C7]USA, San FranciscoChild Health and Development Study66/283Maternal serumHighest versus lowest quartilep,p′-DDT0.790.33--1.89Yes90p,p′-DDE1.180.46--3.02Yes90[@dmw036C83]USA, MichiganMichigan Long-term PBB Study14/431Maternal serumHighest versus lowest (\<LOD). 3 categoriesPBB-153 (includes cryptorchidism)0.710.1--3.8Yes41[@dmw036C15]USA, CaliforniaPregnant women participating in a screening program20/28Maternal serumOR for a 1--10 ng/g lipid change in the analytePBDE-1001.020.74--1.35Yes51PCB-1530.840.30--2.46Yes51HCB0.950.79--1.13Yes51p,p′-DDT10.99--1.01No51p,p′-DDE10.95--1.00No51[@dmw036C28]Italy, RomeChildren enrolled at two Hospitals37/21Mid pregnancy serumAbove versus below medianp,p′-DDE1.180.47--6.91Yes51HCB5.51.25--24.31Yes51PCB (four congeners)1.890.51--6.93Yes51[@dmw036C70]SwedenSouthen Sweden maternity cohort237/237Early pregnancy serumHighest quartile versus lowestPCB-1530.600.30--1.19Yes100p,p′-DDE1.680.92--3.08Yes100HCB1.590.86--2.93Yes100[@dmw036C38]DenmarkPregnancy screening registry, Serum Institute75/300Second trimester amnion fluidHighest tertile versus lowest5cx-MEPP0.890.44--1.80Yes917cx-MMeHP1.690.78--3.67Yes91[@dmw036C88]DenmarkPregnancy screening registry, Serum Institute75/300Second trimester amnion fluidHighest tertile versus lowestPFOS0.690.35--1.38Yes91[^3][^4] Table IVCharacteristics of six case-referent studies (36 risk estimates) addressing the risk of testicular cancer following exposure to endocrine disrupting chemicals.ReferenceLocationStudy population*N* Cases/referentsExposure mediumExposure contrastSubstanceRR95% CICR^[a](#dmw036tfn5){ref-type="table-fn"}^Bias^[b](#dmw036tfn6){ref-type="table-fn"}^[@dmw036C34]SwedenPatients referred to hospital departments in 5 Swedish cities58/61Blood, diagnosed menAbove versus below median in referentsPCB (sum of 38 congeners)1.100.50--2.6091HCB1.700.80--3.6091p,p′-DDE1.700.80--3.7091Chlordane1.300.60--2.809144/45Blood, mothers at time of sons diagnosisAbove versus below median in referentsPCB (sum of 38 congeners)3.801.40--10.091HCB4.401.70--12.091p,p′-DDE1.300.50--3.0091Chlordane1.900.70--5.0091[@dmw036C32]SwedenPatients referred to hospital departments in 5 Swedish cities44/45Blood, mothers at time of sons diagnosisAbove versus below median in referentsPBDE 47, 99, 1532.501.02--6.0091[@dmw036C8]USA, Washing-ton StateThe general population246/630Blood, men when diagnosedAbove 85th percentile versus below 50th percentile in referentsp,p′-DDT1.170.68--2.0091o,p′-DDT1.300.67--2.5391Chlordane (six substances)0.930.51--1.6891HCB0.850.37--1.9691Mirex0.870.50--1.5391Dieldrin0.790.44--1.4191DDE0.610.32--1.1491[@dmw036C58]USAUS servicemen who had donated serum between 1987 and 2002739/915Serum, adult males (bio-banked, (mean storage time 14.2 years))Highest quartile versus lowestDDT1.130.71--1.82110DDE1.711.23--2.38110Chlordane1.511.09--2.10110Mirex1.240.90--1.74110HCCH0.900.65--1.24110[@dmw036C59]USAUS servicemen who had donated serum between 1987 and 2002736/913Serum, adult males (bio-banked, (mean storage time 14.2 years))Highest quartile versus lowestPCB (sum of 11 congeners)0.610.43--0.86110[@dmw036C69]NorwayCitizens with serum stored in the Norwegian cancer Registry49/51Serum, men (pre-diagnostic serum samples from between 1972 and 1978 in the Norwegian Janus Serum Bank)Highest tertile versus lowesto,p′-DDT1.400.40--4.5071p,p′-DDT2.100.60--7.2071p,p′-DDE2.200.70--6.5071Chlordane2.300.60--7.2071Total PCB1.300.50--3.8071Dieldrin2.100.50--9.5071HCB2.900.50--15.2071β-HCCH1.800.50--6.1071λ-HCCH1.100.20--5.0071Mirex1.200.40--3.0071[@dmw036C19]USA, North CaliforniaThe Child Health and Development Studies15/45Early postpartum maternal serumContinuous contrasting 25th--75th interquartile range in controlsp,p′-DDT0.700.26--1.6481p,p′-DDE0.190.04--0.628o,p′-DDT0.770.37--1.33[@dmw036C26]Italy, RomeHospital cases and controls undergoing evaluation for fertility status50/48Serum, extrapolated backwards from male adult valuesAbove versus below LOD (0.2 ng/mL)Sum of p,p′-DDE and HCB3.341.09--10.271[^5][^6] Table VStudies reporting associations between prenatal and postnatal exposure and cryptorchidism or hypospadias without risk estimates (not eligible for meta-analysis).ReferenceLocationStudy populationStudy design*N* populationOutcomeBio- specimenMeasured xenobioticsResultsCR^[a](#dmw036tfn7){ref-type="table-fn"}^Bias^[b](#dmw036tfn8){ref-type="table-fn"}^[@dmw036C36]GermanyChilldren undergoing surgery at one hospitalCross-sectional18/30CryptochidismFat samples26 persistent organochlorine pesticides and PCBs.Median values of 21 among 26 chemicals were higher in cases and two compunds reached statistical significance (HCB and HCE)31[@dmw036C20]Denmark/FinlandDanish--Finnish prospective Birth Cohort StudyCase-referent62/68CryptochidismBreast milk27 biopersistent POPsMedian values of 14 among 27 chemicals were higher in cases. No single compound significantly elevated. Monte Carlo analysis of median values indicated higher levels in cases when the eight compounds with the highest was analysed (*P* = 0.03)90[@dmw036C53]Denmark/FinlandDanish--Finnish prospective Birth Cohort StudyCase-referent95/185 placenta samples, 62/68 milk samplesCryptochidismPlacenta tissue, breast milk14 PBDEsPlacenta: no difference between cases and controls for individual congeners or sum of 14 congeners90Breast milk: no difference between cases and controls for sum of 14 PBDE congeners, while seven individual congenres were significantly higher in cases[@dmw036C98]Denmark/FinlandDanish--Finnish prospective Birth Cohort StudyCase-referent95/185 placenta samples,CryptochidismSerum17 TCDDs and PCDD⁄ Fs) and 37 PCBsNo significant difference between cases and controls with respect to sum of 37 PCBs, PCDD or dioxin equivalents90[@dmw036C78]Northern IndiaChildren with hypospadias and age-matched control childrenCase-referent80/120HypospadiasSerumThree HCH isomers, aldrin, dieldrin, endo I, endo II, p,p′-DDT, p,p,-DDEHigher serum concentrations of all nine pesticides in cases, b-hexachlorohexane (HCH), g-HCH, and p,p′-dichlorodiphenyl -dichloroethylene (p,p′-DDE) significantly higher51[@dmw036C17]Republic of ChoreaNo dataCross-sectional80/80HypospadiasUrine SerumDEHP, DBP, MEHP, MBP, PA, n-NP and t-OPIn urine five of eight substances higher in cases, in serum three substances higher, inconsistent with respect to DEHP (contamination?)21[@dmw036C23]Southern FranceFrench studies on cryptorchidism in Nice and GrasseCase-referent46/106CryptochidismCord bloodBisphenol AMean unconjugated Bisphenol A marginally higher in cases but not significant (*P*= 0.38)61[@dmw036C40]PolandChildren 0--4 years admitted to paediatric departmentCase-referent98/57CryptochidismSerumBisphenol AFree serum BPA level in cryptorchid boys and in the control group was not statistically significant but the conjugated and total serumBPA level was elevated in cryptorchid boys31[^7][^8] Table VIStudies reporting associations between prenatal exposure and sperm count without risk estimates (not eligible for meta-analysis).ReferenceLocationStudy populationStudy design*N* populationBiospecimenMeasured xenobioticsResultsCR^[a](#dmw036tfn9){ref-type="table-fn"}^Bias^[b](#dmw036tfn10){ref-type="table-fn"}^[@dmw036C62]Italy, SevesoExposed men are sons of women living near the Seveso chemical plant at the time of the accident in 1976. Controls were blood donors whose mothers were not exposedMixed design39 exposed /58 referentsMaternal serum in exposed men. Referents had an assumed exposure of 10 pptSerum samples TCDDAverage sperm counts were almost halved in the exposed group and the effect was most pronounced among breast fed men81[@dmw036C95]DenmarkPregnancy cohort, male offspringFollow-up169Maternal serumPFOSPFOA but not PFOS was associated with lower adjusted sperm concentration (p-trend = 0.01)110PFOA[@dmw036C96]DenmarkPregnancy cohort, male offspringFollow-up173Maternal serumPCB (six congeners)Sum PCB and p,p′-DDE was not associated with sperm count110DDE[@dmw036C2]SwedenMainly young men presenting for military health board but also a few from the general population (through announcements in schools)Follow-up112Maternal serumThree DEHP metabolites Three DiNP metabolitesNone of the six phthalate metabolites were associated with Sperm count71[^9][^10] Table VIIORs (95% CIs) of the summary estimate of analyses for associations between endocrine disrupting chemicals and cryptorchidism, hypospadias and testicular cancer. Strata with three or less risk estimates not eligible for meta-analysis. *I*^2^ only available for meta-analyses without bootstrapping (one risk estimate per study).ExposuresOutcomes*N* studies*N* risk estimates (min-max per study)OR95% CI*I*^2^All exposuresAll outcomes1970 (1--10)1.110.91--1.35Cryptorchidism616 (1--7)1.030.72--1.47Hypospadias718 (1--4)1.130.86--1.50Testicular cancer636 (2--10)1.200.78--1.89Bias less likelyAll outcomes522 (2--7)1.120.81--1.57Large studiesAll outcomes934 (1--7)1.060.85--1.33Excluding studies c. testis studies with adult exposure dataAll outcomes1334 (1--7)1.070.87--1.32+ BiopersistenceAll outcomes1766 (1--10)1.150.92--1.44− BiopersistenceAll outcomes34 (1--2)1.120.71--1.77DDEAll outcomes1313 (1)1.351.04--1.7431.91Cryptorchidism33 (1)Hypospadias44 (1)1.380.93--2.040.00Testicular cancer66 (1)1.190.60--2.3678.05DDTAll outcomes66 (1)1.070.81--1.420.00Cryptorchidism11 (1)Hypospadias11 (1)Testicular cancer44 (1)1.120.82--1.550.00PCBAll outcomes99 (1)1.260.82--1.9662.41Cryptorchidism22 (1)Hypospadias44 (1)1.110.61--2.0154.45Testicular cancer33 (1)HCBAll outcomes77 (1)1.190.87--1.6240.94Cryptorchidism11 (1)Hypospadias33 (1)Testicular cancer33 (1)Criteria for exclusion of studies were as follows: *In vitro* and *in vivo* experimental studies.Studies addressing mechanisms and other outcomes related to endocrine disruption, for example, effects on sexual hormone levels in tissues and measures of semen quality other than sperm concentration.Studies based upon chemical analysis of exposure after puberty except studies of testicular cancer.Studies repeating risk estimates reported in previous publications for example, studies addressing risk according to gene polymorphisms for substances, where risk estimates for the entire population were provided earlier.Ecological studies with exposure information at the population level rather than at the individual level.

Search and study selection {#dmw036s7d}
--------------------------

We combined medical subject headings and generic terms for the exposures and outcomes ([Supplementary Table 1](http://HUMUPD.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmw036/-/DC1)) and obtained in total 1314 hits after removal of duplicates. Two authors (JPB and EVB) sifted titles and abstracts independently to assess eligibility and retrieved 110 papers for full text reading. Among these, several reports failed to provide quantitative data on exposure levels and others were excluded for other reasons detailed in [Supplementary Table 2](http://HUMUPD.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmw036/-/DC1). Hand searches of the bibliographies of retrieved primary reports and reviews did not capture additional papers.

We selected 19 epidemiological studies (21 papers) that provided at least one risk estimate for a male reproductive disorder according to at least one measured xenobiotic classified as an endocrine disruptor. Moreover, nine studies (12 papers) that compared average exposure levels in cases and referents without providing risk estimates were included. Thus, the final database comprised 33 papers included for qualitative systematic analysis and 21 papers included for quantitative meta-analysis. No attempt was made to retrieve papers from the unpublished literature. The steps in the literature search are displayed in Fig. [1](#dmw036F1){ref-type="fig"}. Figure 1Flow diagram showing results of a systematic literature search to identify peer review papers addressing risk of male reproductive disorders following prenatal and infancy exposure to environmental endocrine disrupting compounds.

Data extraction {#dmw036s7e}
---------------

Descriptive information (Tables [II](#dmw036TB2){ref-type="table"}--[V](#dmw036TB5){ref-type="table"}) was recorded from each publication using a standardized form constructed prior to the collection process. The standardized data extraction form is provided in [Supplementary Table 3](http://HUMUPD.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmw036/-/DC1). Risk estimates with 95% CI were extracted for each measured compound and outcome. Sperm concentration (sperm count) was taken as the most relevant and robust measure of semen quality despite the substantial within- and between- individual variation ([@dmw036C72]), while other indicators such as motility and morphology were ignored. When risk estimates were available for groups of chemicals, for example, PCB and PBDE congeners and phthalate metabolites, we used the summed risk estimate, if provided. Otherwise, we selected indicator congeners such as PCB-153 and PBDE-100 reflecting levels of all respective congeners. When risk according to several levels of exposure was reported, the highest level versus the reference category was chosen. In one study, the highest level was greater than the 90th percentile ([@dmw036C66]); therefore, we used the next highest exposure category in that study to allow for theoretical inverse relationships. If the relevant relative risks were not reported but data were available, the authors of this paper computed risk estimates and CIs.

Quality assessment {#dmw036s7f}
------------------

### Reporting {#dmw036s7f_1}

Each publication was evaluated for completeness of reporting of the following 11 study characteristics modified after [@dmw036C12]: (i) study design, (ii) sampling frame and procedures, (iii) inclusion and exclusion criteria, (iv) population characteristics of exposed/unexposed or cases/referents, (v) response rates reported or given implicitly, (vi) methods for exposure measurements (reference to method for chemical analysis or detailed description), (vii) criteria for outcome ascertainment, (viii) external quality assurance program of biochemical analyses (certified laboratory and/or participating in analyses of spiked samples from other laboratories), (ix) detection level, recovery and precision (CV) provided on all issues, (x) statistical analysis, and (xi) reporting of exposure--response relationship ([Supplementary Table 3](http://HUMUPD.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmw036/-/DC1)).

We evaluated whether each of these study characteristics were described or not and assigned a value of one if the criterion was fulfilled and zero if not. Giving equal weight to each of the 11 items, we considered completeness of reporting as sufficient if the sum of the 0/1 scores for each paper was ≥8 ([@dmw036C12]). Completeness of reporting is not a direct measure of quality but high completeness is needed for adequate evaluation of bias and confounding.

### Bias and confounding {#dmw036s7f_2}

The decision to limit the review to observational epidemiological studies applying biological monitoring for exposure assessment is considered of major importance to counteract biased findings because of differential recall of exposure often introduced by self-reports or interview information. For each study, other sources of bias were evaluated against a predefined list of seven potential sources of bias and confounding adapted from validated checklists in order to fit the type of studies and research questions addressed in this review ([@dmw036C74]); these are as follows: Reporting of tested hypotheses: Many studies perform multiple comparisons because numerous chemical compounds have been measured. A high risk of bias towards inflated risk estimates is likely if risk estimates are selectively reported compared to objectives or available data.Sample size justification (power calculations and/or addressing sample size in discussion): Small numbers of cases and/or exposed may increase the risk of false negative reporting and thus cause bias towards the null.Selection bias due to attrition in follow-up studies and non-response in case-referent studies: Attrition/non-response \>20% or attrition/non-response differing by \>10% in exposed/cases and unexposed/referents was considered as a potential cause of bias in an unpredictable direction.Information bias (outcome ascertainment): Outcomes identified by patient recall in questionnaires, by interview or medical examination not blinded towards exposure status is a likely cause of inflated risk estimates because of differential exposure misclassification.Confounding: Failure to account by study design or analysis for major potentially confounding factors including maternal age, parity, prematurity, social class and ethnicity was considered as high risk of bias in unpredictable directions. Other potentially confounding factors were considered on an outcome specific basis: Cryptorchidism is a strong risk factor for testis cancer and low sperm count, sexual abstinence and maternal smoking during pregnancy is related to sperm count and the sons age is related to risk of testis cancer. Weak and/or uncertain risk factors such as paternal age, maternal consumption of coffee and alcoholic beverages, infections, malformed uterus and poorly controlled diabetes were not considered.Measuring of confounding factors: Potential bias in an unpredictable direction was considered if measures of confounding factors were invalid or inadequate.Exposure contrast: Studies contrasting exposure levels by the median split rather than by at least exposure-tertiles were considered at risk of bias towards the null because of insufficient exposure contrast.

We considered selective reporting related to multiple testing (1), selection bias (3), information bias related to outcome ascertainment (4) and failure to account for major confounding factors (5) as the most important threats to validity. Accordingly, we categorized a study as at higher risk of bias if two or more of these sources of bias were present.

Risk of bias across studies was evaluated by means of funnel plots to assess risk of publication bias.

Meta-analysis {#dmw036s7g}
-------------

We applied a stepwise approach addressing four different scenarios for the association between chemical exposure and included outcomes with increasing level of specificity. Only cryptorchidism, hypospadias and testicular cancer were included in Steps (1)--(4) below, as none of the four papers addressing sperm count provided risk estimates. The following associations were analysed: The association between all types of endocrine disrupting chemicals with all outcomes assuming that effects occur regardless of specific mechanisms and that the four outcomes are manifestations of the same underlying condition (testicular dysgenesis syndrome;[@dmw036C79]). This analysis assumes that all types of examined individual compounds are proxies for mixtures of substances that carry the same risk for the adverse reproductive outcomes. This assumption is very unlikely to be true, but the analysis is informative when considering global statements on the impact of endocrine disruptors that do not single out individual substances or mixtures of particular concern ([@dmw036C5]).The associations between specific chemicals and all outcomes. Hereby, we account for different endocrine disrupting actions and potencies exhibited by different compounds and address the testicular dysgenesis hypothesis stating that all male reproductive outcomes at least partly are manifestations of the same underlying causal agents operating in early life ([@dmw036C82]; [@dmw036C80], [@dmw036C81]). One study reported multiple PCB and PBDE congener specific risk estimates but no summary estimate ([@dmw036C15]). For this study, we selected the PCB-153 and PBDE-100 as indicators of the total exposure to these compounds and did not include the other congener specific estimates (12 estimates). Another study reported the p,p′-DDE exposure estimate as well as an estimate for the sum of HCB and p,p′-DDE but no separate estimate for HCB (too few cases). In this case, we used the sum of the p,p′-DDE and HCB estimate ([@dmw036C26]).The associations between all exposures and specific outcomes, assuming that endocrine disrupting chemicals in general carry a risk for some but not other male reproductive disorders.Each of the three outcomes individually in relation to specific compounds or group of compounds under the assumption of specific mechanisms and specific outcomes, but without an a priori ranking of more or less likely specific hypotheses. These exploratory analyses have a narrow scope because data are limited. We only included exposure--outcome estimates in the meta-analysis if four or more risk estimates were available.

In sensitivity analyses, we: (i) regrouped compounds into persistent or rapidly metabolised substances with half-lives in the range of hours; (ii) excluded studies with blood sampling after the diagnosis of testicular cancer; (iii) examined the effect of each study on the overall estimate by excluding the studies one at a time; (iv) performed separate analyses of studies with high completeness of reporting and lower risk of bias and confounding as defined above; and (v) performed separate analyses of large case-referent studies with at least 75 cases.

We computed a common risk estimate across studies by weighing the risk ratio (RR) or equivalent (OR or HR) by the inverse variance computed from the mean of the provided confidence limits. This is justified because the outcomes are rare (prevalence \<5%). Random effects estimates are presented regardless of tests for heterogeneity since all studies are conceptually heterogeneous. Nevertheless we also provide *I*^2^ statistics as a formal measure of heterogeneity. Bootstrapping techniques were used in analyses where the same study yielded more than one risk estimate, to account for multiple risk estimates per person in studies where risk estimates were reported for several compounds or outcomes. Bootstrapping with 500 repeats was applied by sampling among all included risk estimates, ensuring that each study only contributed one risk estimate to each bootstrapping step. Mean values across bootstrapped steps were used as overall measures of common risk estimates and confidence limits. These analyses were repeated for each outcome to account for heterogeneity in the exposure--outcome relation.

All statistical analyses were performed using R and a significance level of 0.05. We also used this software to create funnel plots of the standard error by the logarithm of the RR separately for each of the exposures and for the higher quality studies, and inspected these plots for evidence of publication bias.

Results {#dmw036s8}
=======

The study base {#dmw036s8a}
--------------

We identified 33 papers that were based upon 28 independent studies reported 89 associations between measured levels of endocrine disrupting chemicals and one or more of the outcomes: cryptorchidism ([@dmw036C36]; [@dmw036C49]; [@dmw036C66], [@dmw036C67]; [@dmw036C7]; [@dmw036C20]; [@dmw036C53]; [@dmw036C13]; [@dmw036C57]; [@dmw036C23]; [@dmw036C16]; [@dmw036C38]; [@dmw036C40]; [@dmw036C83]; [@dmw036C91]; [@dmw036C97]; [@dmw036C88]; [@dmw036C98]); hypospadias ([@dmw036C49]; [@dmw036C7]; [@dmw036C83]; [@dmw036C57]; [@dmw036C15]; [@dmw036C28]; [@dmw036C17]; [@dmw036C38]; [@dmw036C70]; [@dmw036C91]; [@dmw036C88]); testicular cancer ([@dmw036C34], [@dmw036C33]; [@dmw036C8]; [@dmw036C19]; [@dmw036C26]; [@dmw036C58]; [@dmw036C59]; [@dmw036C69]); and sperm count ([@dmw036C62]; [@dmw036C2]; [@dmw036C95], [@dmw036C96]).

There were 12 papers, based upon nine different study populations, which compared exposure levels in cases and referents but did not provide risk estimates. An overview of eligible studies and risk estimates are given in Tables [II](#dmw036TB2){ref-type="table"}--[IV](#dmw036TB4){ref-type="table"} while the results of three studies (four papers) addressing sperm count and six studies (eight papers) addressing cryptorchidism and hypospadias without risk estimates are displayed in Tables [V](#dmw036TB5){ref-type="table"} and [VI](#dmw036TB6){ref-type="table"}. Most studies addressed persistent organochlorines such as DDE, the metabolite of DDT (18 associations), PCBs (12 associations), DDT and HCB (each 12 associations), while studies on rapidly metabolized compounds such as phthalate ethers and Bisphenol were sparse. The systematic literature search seems to have been efficient since no additional papers fulfilling the eligibility criteria were identified from hand searches of reference lists or reviews. The majority of the studies were case-referent studies, many nested within large well-defined cohorts, while two studies of sperm count were cohort studies ([@dmw036C95], [@dmw036C96]) and two were cross-sectional studies ([@dmw036C62]; [@dmw036C2]). The case-referent studies included a total of 2446 cases of which 671 cases were cryptorchidism, 570 cases were hypospadias and 1205 cases were testicular cancer. In addition 324 men took part in studies of semen quality. Of all of the studies, 19 were published within the past 10 years, of these 13 were carried out in the United States of America or Scandinavia. The completeness of reporting assessed by 11 items were considered high (sum score ≥8 of 11 items) for over 65% of the papers. But less than half of the studies were considered at low risk of bias and confounding. Only five case-referent studies included \>75 cases. Using the form in [Supplementary Table 3](http://HUMUPD.oxfordjournals.org/lookup/suppl/doi:10.1093/humupd/dmw036/-/DC1), we extracted detailed information on each study and including our evaluation of completeness of reporting and potential biases (data available on request). In the following sections, we first present the results of the quantitative meta-analysis and next we review papers that did not report risk estimates.

Global assessment: generic exposures and outcomes as one entity (Hypothesis 1) {#dmw036s8b}
------------------------------------------------------------------------------

The meta-analysis, including all 70 eligible estimates addressing the risk for cryptorchidism, hypospadias or testicular cancer and giving equal weight to each of the xenobiotic exposure indicators, showed an overall risk estimate marginally above unity with rather narrow 95% confidence limits including unity, OR 1.11 (95% CI 0.91--1.35) (Table [VII](#dmw036TB7){ref-type="table"}), and the estimate was similar in studies less likely to be biased, OR 1.12 (95% CI 0.81--1.57). A funnel plot revealed some indication of publication bias as studies with few cases and large standard errors seemed overrepresented among studies with elevated risk estimates (Fig. [2](#dmw036F2){ref-type="fig"}). In a subsequent analysis excluding studies with \<75 cases, we found an attenuated summary estimate (OR 1.06, 95% CI 0.85--1.33) (Table [VII](#dmw036TB7){ref-type="table"}, 'Large studies') but with no indication of publication bias in the corresponding funnel plot (data not shown). Leaving out five estimates originating from studies addressing xenobiotics with rapid metabolism and excretion (phthalates) produced similar results (Table [VII](#dmw036TB7){ref-type="table"}'+biopersistent/-biopersistent'). No single study or exposure had a major impact on the summary risk estimate. Studies addressing p,p-DDT, p,p′-DDE and HCB contributed the most. Figure 2Funnel plot of all risk estimates from all studies included in the meta-analysis (*n*= 70) of the association between prenatal and postnatal exposure to endocrine disrupting environmental chemicals and male reproductive disorders. Risk estimates with identical colors are derived from same study.

Specific exposures and outcomes as one entity (Hypothesis 2) {#dmw036s8c}
------------------------------------------------------------

Data were available for substance specific analyses of risk of any of the reproductive disorders for the most frequently examined compounds (p,p′-DDT, p,p′-DDE, PCB and HCB). Results are summarized in Table [VII](#dmw036TB7){ref-type="table"}. The summary estimate was above unity of all exposures but only statistically significantly elevated for p,p′-DDE (Fig. [3](#dmw036F3){ref-type="fig"}). Figure 3Forest plot of risk estimates (95% CI) from studies included in the boot strap meta-analysis of the association between prenatal and postnatal exposure to DDE and cryptorchidism, hypospadias or testicular cancer (*N*= 13).

Generic exposures and specific outcomes (Hypothesis 3) {#dmw036s8d}
------------------------------------------------------

### Cryptorchidism {#dmw036s8d_1}

Ten case-referent studies based upon six study populations provided 16 risk estimates for cryptorchidism (Fig. [4](#dmw036F4){ref-type="fig"}). The most frequently studied exposures were persistent organochlorine pesticides and PCBs which were measured in maternal pregnancy or postpartum blood samples, or cord blood or breast milk, and one study used amnion fluid to assess exposure to phthalates and perfluorooctane sulfonic acid (PFOS). Among the 16 risk estimates, nine were above unity and four exceeded a relative risk of 2. The meta-analytic summary estimate was close to unity, OR 1.03 (95% CI 0.72--1.47), Fig. [4](#dmw036F4){ref-type="fig"}. Funnel plots did not indicate publication bias (data not shown). Figure 4Forest plot of the risk estimates from studies included in the meta-analysis of the association between prenatal and postnatal exposure to endocrine disrupting environmental chemicals and cryptorchidism (*n*= 16).

### Hypospadias {#dmw036s8d_2}

Nine case-referent studies based upon seven study populations addressed links between xenobiotics and hypospadias and all studies except one measured xenobiotics in maternal serum (Fig. [5](#dmw036F5){ref-type="fig"}). Five of the studies also reported on cryptorchidism. Among 18 risk estimates, 11 were above unity and seven were below and one relative risk exceeded 2. The summary estimate was close to unity, OR 1.13 (95% CI 0.86--1.50), Table [VII](#dmw036TB7){ref-type="table"}. Funnel plots did not indicate publication bias (data not shown). Figure 5Forest plot of risk estimates (95% CI) from studies included in the boot strap meta-analysis of the association between prenatal and postnatal exposure to endocrine disrupting environmental chemicals and hypospadias (*n* = 18).

### Testicular cancer {#dmw036s8d_3}

Eight case-referent studies based upon six study populations examined risk of testicular cancer according to environmental exposure to potential endocrine disruptive chemicals (Fig. [6](#dmw036F6){ref-type="fig"}). Two early Swedish studies measured xenobiotics at the time of diagnosis in the men and in a subset of their mothers at the same time ([@dmw036C34], [@dmw036C32]), while a few later studies targeted the hypothesis of prenatal origins of testicular cancer assuming that persistent organic pollutants in prediagnostic serum samples of young men was a useful proxy of *in utero* exposure and early infancy exposure ([@dmw036C8]; [@dmw036C26]; [@dmw036C58]). Only a single study was based on maternal serum samples ([@dmw036C19]). Altogether, the eight case-referent studies provided 36 risk estimates with DDT being the most frequently examined compound (seven estimates). Of these, 26 estimates were above unity and nine exceeded a relative risk of 2. The summary estimate was slightly elevated but not statistically significantly different from one, OR 1.20 (95% CI 0.78--1.89). The funnel plot was compatible with publication bias since small studies contrary to large studies reported a non-proportional large number of elevated risk estimates (data not shown). Figure 6Forest plot of risk estimates (95% CI) from studies included in the boot strap meta-analysis of the association between exposure to endocrine disrupting environmental chemicals and testicular cancer (*n* = 36).

### Sperm count {#dmw036s8d_4}

No risk estimates available.

Specific exposures and specific outcomes (Hypothesis 4) {#dmw036s8e}
-------------------------------------------------------

Available data for specific exposure and specific outcomes are limited. Four or more risk estimates were only available for four exposure--outcome combinations. Results of the conventional meta-analysis without bootstrapping (since risk estimates are independent) are shown in Table [VII](#dmw036TB7){ref-type="table"}. The summary relative risk estimates were slightly above unity but none were statistically significant.

Studies not eligible for meta-analysis {#dmw036s8f}
--------------------------------------

### Cryptorchidism {#dmw036s8f_1}

Six case-referent studies based upon four independent study populations did not provide risk estimates but compared concentrations of xenobiotics in fat samples, breast milk, placenta tissue, maternal serum or cord blood in cases and controls ([@dmw036C36]; [@dmw036C20]; [@dmw036C53]; [@dmw036C23]; [@dmw036C40]; [@dmw036C98]), Table [V](#dmw036TB5){ref-type="table"}. Altogether these papers report 104 exposure--outcome comparisons, ignoring that some studies examined compounds in more than one type of biological medium. The findings with respect to biopersistent organochlorines results are largely consistent with the findings in the quantitative meta-analysis, showing limited evidence of associations. This also applies to studies with high completeness of reporting and less likely risk of bias, that addressed PBDE, TCDD, PCDD and organochlorine pesticides (Table [V](#dmw036TB5){ref-type="table"}). Bootstrapping analyses of the subset of the seven substances with highest breast milk concentrations indicated higher median values in cases but this may be a chance finding since the overall analysis of all compounds was non-significant ([@dmw036C20]). The study on brominated flame retardants found increased levels in breast milk samples among cases, but this result was not confirmed in analyses based upon corresponding placenta tissue samples, which a priori were thought to provide the most accurate measure of fetal exposure ([@dmw036C53]). Findings in other studies mainly addressing rapidly metabolized contaminants were also reassuring, but these studies were considered at high risk of bias (Table [V](#dmw036TB5){ref-type="table"}).

### Hypospadias {#dmw036s8f_2}

Two studies, not providing best practice reporting and considered at higher risk of bias, did not provide risk estimates but compared concentrations of xenobiotics in blood and urine samples in cases and controls ([@dmw036C78]; [@dmw036C17]; Table [V](#dmw036TB5){ref-type="table"}). In the first study, compounds with short biological half-lives were examined and three out of eight substances were elevated in serum samples compared to controls but these results were not entirely consistent with results based upon urine samples ([@dmw036C17]). The other study examined nine biopersistent pesticides and observed higher concentrations in serum from cases for them all ([@dmw036C78]).

### Sperm count {#dmw036s8f_3}

To date only three studies (four papers) explicitly studying xenobiotic prenatal exposure to potential endocrine disrupting compounds relative to semen quality in adult men have been published (Table [VI](#dmw036TB6){ref-type="table"}). These studies are highly heterogeneous with respect to design and xenobiotics and a meta-analysis is not appropriate. Rather than providing risk estimates for reduced sperm count these studies report measures of average sperm counts according to the level of xenobiotic. Sons of women living near a chemical plant exposed to dioxin due to an accident in 1976 that contaminated the surroundings were identified in a seminal study and serum dioxin concentration at the time of conception during the period 1977--1984 was estimated based upon bio-banked maternal serum samples. Sperm counts in the exposed group of sons were compared with counts from men with assumed background exposure. Average sperm counts were almost halved in the exposed group and the effect was most pronounced among men who had been breastfed during childhood ([@dmw036C62]). The sample included only 39 exposed men and was too small to allow for exposure-response analysis. In a Danish study, sons of mothers with biobanked serum samples provided semen samples when they were 19--21 years of age and sperm count was examined according to tertiles of maternal serum concentration of a range of compounds. There was no indication that PCBs, the DDT metabolite DDE or PFOS were associated with reduced sperm count, but high level PFOA exposure was significantly associated with reduced sperm concentration ([@dmw036C95], [@dmw036C96]). Finally, a Swedish cross-sectional study using biobanked maternal serum samples did not show associations between sperm count and a range of phthalate metabolites ([@dmw036C2]).

Discussion {#dmw036s9}
==========

This is the first systematic review with meta-analysis that has rigorously evaluated the epidemiological evidence on prenatal and postnatal exposure to endocrine disrupting compounds and male reproductive disorders. A total of 33 papers provided 89 risk estimates on which we found no strong support for a global effect as a whole or on any specific outcome. However, one of four specific compounds with sufficient data to allow for meta-analysis were related to a moderate increased risk of all outcomes taken together (p,p′-DDE). Although only limited data were available for specific exposure--outcome associations, these findings do not seem to be due to increased risk of any single included disorder (cryptorchidism, hypospadias or testicular cancer). Thus findings provide some support to the hypothesis of shared prenatal etiology of these outcomes, but they also point to heterogeneity of compounds classified as endocrine disruptors with respect to potential effects on male reproduction.

The strength of this review in comparison with narrative reviews and global assessments is primarily that it includes, to our knowledge, all published epidemiological evidence fulfilling predefined criteria using a systematic and transparent search of the literature. Although the findings of this review provide some evidence for environmental endocrine disruption of male reproductive function, the limitations of observational epidemiology and the outcomes reported in the few available high quality studies precludes strong concluding statements.

Exposure assessment {#dmw036s9a}
-------------------

Reliable exposure assessment is essential in environmental epidemiology and measurements of the compounds of interest are considered as the gold standard. We therefore only included studies with actual measurements of the chemicals in tissues as exposure assessment based on external determinants (such as job title) is crude when it comes to endocrine disrupting chemicals. Analyses of blood or tissue concentrations of chemicals were performed by gas chromatography/mass spectrometry and most studies provided data on recovery and between batch coefficients of variation. Although differences in sample preparation, analytical technique and units may invalidate comparisons of absolute exposure levels across studies, this is not expected to affect risk estimates that are derived from within-study contrasts of exposure levels.

Misclassification of exposure at the susceptible periods of development most likely results in bias towards the null. Most studies measured the contaminants late in pregnancy, at birth or during lactation and not precisely at the time of differentiation of the male gonads, that based upon animal studies in the rat, is assumed to take place in gestational week 8--14 ([@dmw036C99]; [@dmw036C51]). Considering the long half-lives of the persistent chemicals with little expected fluctuation of tissue levels across a few months, measurements around the time of birth seems a reasonable proxy for exposure levels during early pregnancy although distribution kinetics during pregnancy may be an issue ([@dmw036C94]). This is entirely different for compounds with a rapid metabolism and excretion such as phthalates and bisphenol A, which fluctuate markedly within individuals as shown in studies with repeated sampling. Thus, in a study where three blood samples were taken during pregnancy the intra-class coefficient of variation were for most phthalate metabolites between 20% and 40% ([@dmw036C14]). However, at the group level serum levels of metabolites were remarkably stable. The direction of bias may be in either direction in the individual study but tends, on average, to cause bias towards null. One of the included studies measuring phthalate metabolites in amnion fluid in the second trimester found no association with cryptorchidism and hypospadias even though one DEHP metabolite was related to higher fetal testosterone and lower insulin-like factor III ([@dmw036C38]).

Assessment of fetal exposure using maternal blood or milk samples assumes that the placenta is not an efficient barrier for chemical transfer from the maternal to the fetal circulation and that fetal exposure is proportional to maternal exposure. It is therefore noteworthy that knowledge regarding the transport of persistent xenobiotics over the placenta to the fetus has been known for decades ([@dmw036C64]; [@dmw036C55]). More recent findings indicate that rapidly metabolized compounds also pass through the placenta and these have been detected in cord blood and amnion fluid ([@dmw036C38]).

Exposure contrast within and across studies {#dmw036s9b}
-------------------------------------------

The most prevalent persistent organochlorine contaminants were banned in high income countries during the 1970s and subsequently their tissue levels have declined substantially. However, the studies included in this review encompass studies based upon samples biobanked \>50 years ago such as the Collaborative Perinatal Study with relatively high serum concentrations ([@dmw036C49]; [@dmw036C67]; [@dmw036C58], [@dmw036C59]; [@dmw036C91]) as well as studies based upon sampling much later ([@dmw036C20]; [@dmw036C53]; [@dmw036C98]). Unfortunately, data are too sparse to allow for a formal meta-analysis based upon the variation in exposure levels in reference populations throughout time; however, no individual studies with large exposure contrast found evidence for a relationship between exposure and response.

Since this review is focused upon prenatal exposures, we excluded a wealth of cross-sectional studies linking occupational and environmental exposure in adulthood with semen quality (for a recent review and a large collaborate study summary, see [@dmw036C11]; [@dmw036C9]). In contrast to testicular cancer, it is well established that spermatogenesis is susceptible to short-term effects of reproductive toxicants not least in the workplace.

Outcome ascertainment {#dmw036s9c}
---------------------

The male reproductive disorders addressed in this review are distinct diseases with different pathologies, clinical characteristics and age of appearance. Cryptorchidism and hypospadias were either defined by specified criteria applied in systematic examinations of newborns in prospective studies or from medical records. Although criteria for both disorders may differ substantially and contribute to apparent secular trends and spatial shifts in prevalence rates, it is unlikely that differences in outcome ascertainment across studies disrupt the internal validity and the relative risk estimates. No studies used participant questionnaires or interviews to define outcomes and therefore recall bias is not an issue in studies included in this review.

The testicular dysgenesis syndrome hypothesis {#dmw036s9d}
---------------------------------------------

We analyzed the male reproductive disorders, with the exception of low sperm count where no risk estimates were available, as one entity with reference to the testicular dysgenesis syndrome hypothesis on shared etiology of the four male reproductive disorders ([@dmw036C79]) and with reference to experimental evidence suggesting multiple mechanistic pathways of endocrine disruption ([@dmw036C89]). The strength of the testicular dysgenesis syndrome hypothesis and the applicability of this concept as explanation of the pathogenesis of the majority of its components is an important pre-requisite for obtaining statistically significant associations when testing hypotheses I and II, where cryptorchidism, hypospadias and testicular cancer were merged together as end points in statistical analyses. However, the heterogeneity of the pathogenesis underlying those conditions and their relative weak or moderate mutual clinical associations might indicate that only a minor proportion of these male reproductive abnormalities fit into the testicular dysgenesis syndrome concept ([@dmw036C87]), which may explain the generally non-significant or only weakly statistically significant findings of our analyses.

Studies addressing testicular cancer {#dmw036s9e}
------------------------------------

Although focus was on developmental disorders induced by chemical exposure during critical time windows in early life ([@dmw036C46]), there only exists one small study using prenatal or postnatal bio-specimens to assess testicular cancer ([@dmw036C19]). We therefore included six studies on testicular cancer assessing exposure by measurement of chemicals in serum samples obtained after puberty. Hereby, we assume that serum levels of persistent chemicals in young men or their mothers are reasonable proxies for prenatal and postnatal exposure. There is however some evidence to support this strong assumption. First of all, the biological half-lives of many of these compounds are counted in decades ([@dmw036C31]). Moreover, studies in a Faroese birth cohort demonstrated strong intra-individual correlations between persistent chemicals in cord blood and serum concentrations at 7 and 14 years of age, respectively ([@dmw036C4]). Another study found high correlations of persistent chemical levels in serum samples in adult men obtained up to 10 years apart ([@dmw036C31]). Finally, a history of breastfeeding was related to elevated serum levels in men up to 40 years later in one study ([@dmw036C8]). Although adult serum concentrations of persistent chemicals may to some extent reflect prenatal and early postnatal exposure, it is obvious that varying rates of metabolism as well as additional lifetime exposures during infancy, childhood and adulthood also contribute to exposure levels. The resulting misclassification most is most likely is towards the null. Accordingly it is not surprising that the overall risk estimate was attenuated in the analysis excluding studies on testis cancer with adult serum data only.

Studies addressing sperm count {#dmw036s9f}
------------------------------

Although the effects of endocrine disrupting chemicals on male fertility has been the focus of heated debate ([@dmw036C10]), only three human studies have to date linked prenatal and postnatal exposure to xenobiotics with sperm count in adults ([@dmw036C62]; [@dmw036C2]; [@dmw036C95]). This is probably explained by the difficult and costly logistics of population-based semen studies and the need for maternal biospecimens or cord blood stored decades before follow-up takes place. In the study by Mocarelli *et al*., the findings of halved sperm counts in men whose mothers were exposed to higher levels of dioxin when pregnant are intriguing but call for cautious interpretation. Exposure levels in women living in the contaminated area are overlapping the background exposure, participants are few, referents are from a convenience sample and significant results were limited to the subgroup of men breast-fed as infants ([@dmw036C62]). The pertinent question is whether sperm counts in the exposed group are low (in the range of 45 mill/mL) or whether sperm counts in the reference group are high (in the range of 80 mill/mL). It is well established that small cross-sectional semen studies are highly vulnerable to selection bias ([@dmw036C44]). Unfortunately it is hardly possible to replicate the findings. Results from the sole study that was explicitly designed to test the hypothesis on delayed effects on sperm count are reassuring with respect to organochlorines ([@dmw036C96]), but less so with respect to the much less studied but ubiquitous perfluorinated hydrocarbons ([@dmw036C95]). The Swedish study addressing phthalate metabolites did not reveal adverse effects but exposure assessment of the rapidly metabolized compounds with high within-day and between-days variation within individuals is an issue. Nevertheless single spot urine samples may distinguish different exposure levels at the population level if study populations are sufficiently large ([@dmw036C31]; [@dmw036C68]; [@dmw036C103]). Obviously there is a need to design future studies with sufficient power to examine exposure--response associations. With the aging large European birth cohorts with stored maternal serum samples, this will become feasible in a few years.

Methodological issues {#dmw036s9g}
---------------------

Many of the included studies examined several compounds for which risk estimates are not independent. This was accounted for by the use of bootstrapping statistical techniques by which analyses are iterated several hundred times randomly including only one risk estimate per population in each analysis and providing an average risk estimate giving equal weight to studies with few and many risk estimates. This method does not provide statistics for heterogeneity which is considered less of a problem since study populations and risk estimates obviously are heterogeneous. Therefore, we used random effects models rather than fixed effects models in all analyses. In spite of strong heterogeneity across studies with respect to study populations, exposures and outcomes, it is remarkable that all summary risk estimates from substance and outcome specific supplementary analyses are of similar magnitude spanning a relative risk from 1.03 to 1.26 when ignoring one outlying observation.

The number of studies addressing specific chemicals and outcomes were few and did not permit robust meta-analysis. Therefore, this review is primarily informative with respect to the overall association and the hypothesis on shared etiology. A number of studies did not report risk estimates but used other measures of associations. However, those findings did not seem to deviate from the overall picture.

Since we only included studies that documented exposure by objective analysis of compounds in biological media, the often encountered risk of bias due to differential recall of exposure or outcome was bypassed. Selection bias related to prior knowledge about levels of contaminants in biological tissues among patients or researchers therefore also seems unlikely. Few, if any, know their own tissue concentrations of the investigated contaminants to which all persons are exposed. Moreover, the nested case-referent design adopted by the majority of the included studies promotes comparability of cases and referents with respect to social and behavioral factors that may be related to exposure levels and thus indirectly cause bias. The two main reasons for rating some studies at a higher risk of confounding was either due to lack of or insufficient adjustment for potential confounding factors such as maternal age and prematurity in case of congenital malformations with unpredictable direction of bias or small study size that was not justified by power calculations which may increase the risk of publication bias. In fact funnel plots indicated overrepresentation of higher risk estimates in small studies with larger standard errors. Selective reporting did not appear to be a problem. All studies seemed to provide data on all measured substances regardless of association. Finally, only a few studies corrected for weight gain during pregnancy which may cause false positive associations due to dilution of the distribution volume for biopersistent chemicals ([@dmw036C94]), an issue if the outcome is related to lower birthweight or congenital malformations.

Nevertheless, the findings must be interpreted in the light of the complexity of this research field. Thus, the meta-analyses strongly violates basic assumptions in that populations, chemical substances and outcomes differ across studies ([@dmw036C71]), which necessarily must result in substantial heterogeneity disregarding results of any statistical test. The meta-analytic summary estimates and their confidence limits are not quantitatively reliable measures of specific exposure--outcome relations but merely serve to provide an overview of the available limited evidence.

Cocktail effects {#dmw036s9h}
----------------

Humans are simultaneously exposed to a plethora of hundreds of xenobiotics. Some *in vitro* and *in vivo* animal studies have demonstrated combined effects of endocrine disrupting chemicals at levels at which the individual chemicals do not induce observable effects ([@dmw036C41]; [@dmw036C42]). Because of this 'cocktail effect' of mixtures, scientist have criticized epidemiological studies for most often addressing effects of individual chemicals one by one. However, this criticism ignores to some extent that persistent organic pollutants are highly correlated and epidemiological studies addressing one indicator chemical, for example PCB-153, are in fact reflecting exposure to a mixture of numerous other chemicals. For example, in a study of persistent organic pollutants and fertility, it was not possible to distinguish between the potential effects of PCBs and the DDT metabolite DDE ([@dmw036C3]).

Non-monotonic dose--response relationships {#dmw036s9i}
------------------------------------------

Another concern is the possibility of non-monotonic dose--response relationships which may explain apparently inconsistent findings across studies because of different levels and ranges of exposures ([@dmw036C93]). This is particularly a potential problem when extrapolating from high occupational exposure levels to low environmental levels and in risk assessment with a need to extrapolate from high doses in *in vitro* and *in vivo* animal studies to many-fold lower environmental levels that humans encounter. However, the possibility of non-monotonic dose--response relationship is less of a problem in large population-based studies capturing a broad low-level exposure range ([@dmw036C46]). None of the large studies included in this review with substantial exposure contrast and comprehensive evaluation of risk according to exposure strata indicate the existence of such non-monotonic exposure--response relationships ([@dmw036C50], [@dmw036C49]).

Wider implications and conclusion {#dmw036s9j}
---------------------------------

The widely stated view that ubiquitous endocrine disrupting chemicals in our environment play a substantial role in the development of male reproductive disorders through prenatal and perinatal mechanisms is to some extent challenged by this review. Although the current epidemiological evidence is compatible with a small increased risk of male reproductive disorders following prenatal and postnatal exposure to some persistent environmental chemicals classified as endocrine disruptors, the evidence is limited. In this light, estimates of the burden of disease and costs of exposure to endocrine chemicals ([@dmw036C92]) seem highly speculative, at least with respect to male reproductive disorders. Future epidemiological studies may change the weight of the evidence in either direction and the need for appropriate risk assessment of chemicals based upon experimental evidence should not be ignored. There are insufficient data on rapidly metabolized endocrine disruptors and specific exposure--outcome relations. A particular data gap is evident with respect to delayed effects on semen quality and testicular cancer.
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